Overview

To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate long-term safety and efficacy of pregabalin in patients with postherpetic neuralgia.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Treatments:
Pregabalin
Criteria
Inclusion Criteria:

- Must have met the inclusion criteria for preceding double-blind BID study in
postherpetic neuralgia

- Must have received pregabalin/placebo under double-blind conditions for a minimum of 3
weeks.

Exclusion Criteria:

- Patients cannot participate if they experienced a serious adverse event during
preceding double-blind BID study which was determined to be related to the study
medication.